RU2018145045A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018145045A3 RU2018145045A3 RU2018145045A RU2018145045A RU2018145045A3 RU 2018145045 A3 RU2018145045 A3 RU 2018145045A3 RU 2018145045 A RU2018145045 A RU 2018145045A RU 2018145045 A RU2018145045 A RU 2018145045A RU 2018145045 A3 RU2018145045 A3 RU 2018145045A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662339773P | 2016-05-20 | 2016-05-20 | |
US62/339,773 | 2016-05-20 | ||
US201662432152P | 2016-12-09 | 2016-12-09 | |
US62/432,152 | 2016-12-09 | ||
PCT/US2017/033634 WO2017201468A1 (en) | 2016-05-20 | 2017-05-19 | Benzenesulfonamide compounds and their use as therapeutic agents |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018145045A RU2018145045A (ru) | 2020-06-22 |
RU2018145045A3 true RU2018145045A3 (ru) | 2020-06-22 |
RU2769827C2 RU2769827C2 (ru) | 2022-04-06 |
Family
ID=58794232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018145045A RU2769827C2 (ru) | 2016-05-20 | 2017-05-19 | Соединения бензолсульфонамида и их применение в качестве терапевтических средств |
Country Status (17)
Country | Link |
---|---|
US (4) | US10246453B2 (ru) |
EP (1) | EP3458449A1 (ru) |
JP (3) | JP6938545B2 (ru) |
KR (1) | KR102366077B1 (ru) |
CN (1) | CN109526219B (ru) |
AU (2) | AU2017268006B2 (ru) |
CA (1) | CA3023465A1 (ru) |
CL (1) | CL2018003260A1 (ru) |
CO (1) | CO2018012485A2 (ru) |
IL (1) | IL262834B (ru) |
MX (1) | MX2018013985A (ru) |
PH (1) | PH12018502378A1 (ru) |
RU (1) | RU2769827C2 (ru) |
SG (2) | SG11201809702SA (ru) |
TN (1) | TN2018000385A1 (ru) |
WO (1) | WO2017201468A1 (ru) |
ZA (1) | ZA201807518B (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109526219B (zh) | 2016-05-20 | 2021-03-12 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
RU2760303C2 (ru) | 2016-12-09 | 2021-11-23 | Ксенон Фармасьютикалз Инк. | Соединения бензолсульфонамидов и их использование в качестве терапевтических средств |
JP7371029B2 (ja) | 2018-06-13 | 2023-10-30 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
EA202190395A1 (ru) | 2018-08-31 | 2021-06-15 | Ксенон Фармасьютикалз Инк. | Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств |
CA3104913A1 (en) * | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
WO2022077094A1 (en) * | 2020-10-13 | 2022-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels |
TW202220647A (zh) * | 2020-10-13 | 2022-06-01 | 加拿大商再諾製藥公司 | 用於治療與電位閘控型鈉通道相關聯之疾病的醫藥調配物 |
WO2023235734A1 (en) * | 2022-06-02 | 2023-12-07 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
PT981327E (pt) | 1997-05-07 | 2003-02-28 | Galen Chemicals Ltd | Dispositivos intravaginais de libertacao de farmacos para a administracao de testosterona e percursores da testosterona |
BR9916885A (pt) | 1999-01-13 | 2001-11-20 | Warner Lambert Co | Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek |
DE60005688T2 (de) | 1999-07-16 | 2004-04-29 | Warner-Lambert Co. Llc | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer |
GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
JP2009513523A (ja) | 2003-07-08 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物 |
AR045238A1 (es) | 2003-08-08 | 2005-10-19 | Vertex Pharma | Compuestos utiles como inhibidores de canales ionicos regulados por voltaje |
HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
WO2006066109A2 (en) | 2004-12-17 | 2006-06-22 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
CN101277940A (zh) | 2005-10-06 | 2008-10-01 | 塞诺菲-安万特股份有限公司 | 4-氧基-n-[1,3,4]-噻二唑-2-基-苯磺酰胺、它们的制备方法及它们作为药物的用途 |
CN101365686A (zh) * | 2005-12-21 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的杂环衍生物 |
BRPI0715967A2 (pt) * | 2006-08-15 | 2013-08-06 | Hoffmann La Roche | compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodos para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de sst do subtipo 5, e uso destes compostos |
CA2666624C (en) | 2006-10-19 | 2015-12-29 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
US8853250B2 (en) | 2007-07-13 | 2014-10-07 | Icagen, Inc. | Sodium channel inhibitors |
WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
US7846954B2 (en) | 2008-07-01 | 2010-12-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
RS53941B1 (en) | 2009-01-12 | 2015-08-31 | Pfizer Limited | SULFONAMID DERIVATIVES |
JP5830534B2 (ja) | 2010-07-09 | 2015-12-09 | ファイザー・リミテッドPfizer Limited | 化合物 |
CN103119045B (zh) | 2010-08-20 | 2016-02-17 | 和记黄埔医药(上海)有限公司 | 吡咯并嘧啶化合物及其用途 |
EP2744805A1 (en) | 2011-08-17 | 2014-06-25 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
RU2014121489A (ru) | 2011-10-28 | 2015-12-10 | Мерк Шарп И Доум Корп. | Соединения бензоксазолинона с селективной активностью в отношении потенциалзависимых натриевых каналов |
RU2014121984A (ru) * | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
MX2014005304A (es) * | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
ES2828503T3 (es) | 2012-10-15 | 2021-05-26 | Dae Woong Pharma | Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos |
EP2911668A4 (en) | 2012-10-26 | 2016-07-20 | Merck Sharp & Dohme | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS |
KR20150074123A (ko) | 2012-10-26 | 2015-07-01 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 n-치환된 인다졸 술폰아미드 화합물 |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
US9663469B2 (en) | 2013-09-09 | 2017-05-30 | Bristol-Myers Squibb Company | RORγ modulators |
SG11201601367QA (en) | 2013-09-10 | 2016-03-30 | Chromocell Corp | Sodium channel modulators for the treatment of pain and diabetes |
EP3074377B1 (en) * | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
CN106103415B (zh) | 2013-12-23 | 2023-02-24 | 普渡制药公司 | 吲唑和其用途 |
JP2017525677A (ja) * | 2014-07-07 | 2017-09-07 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
WO2016177340A1 (zh) | 2015-05-05 | 2016-11-10 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
CN109069489A (zh) | 2015-12-18 | 2018-12-21 | 默沙东公司 | 对电压门控性钠通道具有选择性活性的二氨基-烷基氨基连接的芳基磺酰胺化合物 |
CN109526219B (zh) | 2016-05-20 | 2021-03-12 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
US10968210B2 (en) | 2016-11-17 | 2021-04-06 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
RU2760303C2 (ru) | 2016-12-09 | 2021-11-23 | Ксенон Фармасьютикалз Инк. | Соединения бензолсульфонамидов и их использование в качестве терапевтических средств |
JP7371029B2 (ja) * | 2018-06-13 | 2023-10-30 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
CA3104913A1 (en) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
-
2017
- 2017-05-19 CN CN201780042625.6A patent/CN109526219B/zh active Active
- 2017-05-19 RU RU2018145045A patent/RU2769827C2/ru active
- 2017-05-19 MX MX2018013985A patent/MX2018013985A/es unknown
- 2017-05-19 CA CA3023465A patent/CA3023465A1/en active Pending
- 2017-05-19 JP JP2018560884A patent/JP6938545B2/ja active Active
- 2017-05-19 KR KR1020187036489A patent/KR102366077B1/ko active IP Right Grant
- 2017-05-19 SG SG11201809702SA patent/SG11201809702SA/en unknown
- 2017-05-19 US US15/600,490 patent/US10246453B2/en active Active
- 2017-05-19 SG SG10201912216VA patent/SG10201912216VA/en unknown
- 2017-05-19 AU AU2017268006A patent/AU2017268006B2/en active Active
- 2017-05-19 EP EP17726487.6A patent/EP3458449A1/en active Pending
- 2017-05-19 WO PCT/US2017/033634 patent/WO2017201468A1/en unknown
- 2017-05-19 TN TNP/2018/000385A patent/TN2018000385A1/en unknown
-
2018
- 2018-11-06 IL IL262834A patent/IL262834B/en unknown
- 2018-11-08 ZA ZA2018/07518A patent/ZA201807518B/en unknown
- 2018-11-12 PH PH12018502378A patent/PH12018502378A1/en unknown
- 2018-11-16 CL CL2018003260A patent/CL2018003260A1/es unknown
- 2018-11-21 CO CONC2018/0012485A patent/CO2018012485A2/es unknown
-
2019
- 2019-02-28 US US16/289,212 patent/US10662184B2/en active Active
-
2020
- 2020-03-17 US US16/821,294 patent/US10815229B1/en active Active
- 2020-07-28 US US16/940,696 patent/US11299490B2/en active Active
-
2021
- 2021-06-08 AU AU2021203771A patent/AU2021203771B2/en active Active
- 2021-09-01 JP JP2021142186A patent/JP2021185189A/ja not_active Withdrawn
-
2023
- 2023-06-16 JP JP2023099277A patent/JP2023108032A/ja active Pending
Also Published As
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HE9A | Changing address for correspondence with an applicant |